NCT00005571View on ClinicalTrials.gov

Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2000

Study Completion Date

December 31, 2001

Conditions
Dermatomyositis
Interventions
DRUG

h5G1.1-mAb

Trial Locations (1)

20892

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00005571 - Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis | Biotech Hunter | Biotech Hunter